Upload
bahadir-dogan
View
17
Download
4
Tags:
Embed Size (px)
Citation preview
“A leader in healthcare”
TIM503 spring 2015 Case study on Technology Identification Bahadır Doğan 209MIE8020
Presentation Outline
• Company Profile
• Corporate Overview
• Global Presence
• History
• Technology Identification
• Corporate Technology Sourcing Unit
• Baxter Ventures
• Questions & Closure
Corporate Overview
• Develops, manufactures and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions
• 2014 sales of $16.7 billion and has approximately 65,500 employees
• Baxter products are infused, injected or inhaled approx. 6 million times a day
Corporate Overview
60%
40%
2014 Sales by Business
Medical Products (hemophilia; immune deficiencies, other blood-related conditions)
BioScience (intravenous solutions, infusion pumps, inhalation anesthetics)
Corporate Overview
42%
31%
11%
16%
2014 Sales by Region
U.S.
Europe
Latin America / Canada
Asia Pacific
Corporate Overview
Regional Employee Breakdown
2012 2013 2014
United States 20,300 22,000 23,000
Europe 15,500 21,000 21,000
Latin America/Canada 6,875 8,500 9,100
Asia Pacific 8,100 9,700 12,000
Total 50,800 61,500 65,500
Corporate Overview
$-
$500
$1,000
$1,500
2010 2011
2012 2013
2014
$915 $946 $1,156 $1,246
$1,421
R&D Expenditures (in millions $)
• “ ... medical firsts; the first commercially manufactured (IV) solutions to the first portable kidney dialysis machine ... Baxter
continually pursues breakthrough technologies through research facilities around the world, and our investments reflect that
commitment. ”
clinical differentiation
inlicensing, milestone
reimbursement payments
made to partners for
R&D
Corporate Overview
• The company continues to focus on four key strategic growth vectors (objectives)
• advancing the core portfolio globally,
• driving innovation through the R&D pipeline,
• enhancing growth through acquisitions
• collaborations, and developing unique public-private partnerships.
Global Presence
• Global presence and infrastructure is one of Baxter's key strengths
• In 2014, nearly 60 percent of Baxter's sales and workforce were outside the United States
• North America Baxter has facilities in 12 states and Puerto Rico. HQ located in Deerfield, Illinois, approximately 30 miles north of Chicago.
Global Presence
• Has significant presence in Europe, Middle East and Africa, with manufacturing and research facilities in more than a dozen countries including Austria, Belgium, Czech Republic, France, Germany, Ireland, Italy, Malta, Poland, Spain, Sweden, Switzerland and the United Kingdom.
Global Presence
• Latin America/Canada region includes Baxter manufacturing and distribution facilities in Argentina, Brazil, Canada, Colombia, Costa Rica, Dominican Republic and Mexico.
• Has had a significant Asia Pacific presence for more than 40 years. Five sub-regions: Japan, China, North Asia, Australia/New Zealand and India/Southeast Asia.
History
• 1931 - first manufacturer of commercially prepared IV solution
• 1939 - named Baxter Laboratories, introduced the Transfuso-Vac container, the first sterile, vacuum-type blood collection and storage unit. Before, blood could be stored for only a few hours; new container allowed storage for up to 21 days
History
• 1941- introduced the Plasma-Vac container, separating plasma from whole blood, storing it for future use.
• 1956 - Dr. Kolff’s kidney dialysis machine (made up of orange juice cans and a washing machine) collaboratively developed by Mr. Graham & Baxter engineers. Finally, introduced first commercially built artificial kidney for end-stage renal disease.
History
• 1959 - acquired Fenwal Lab: Blood-pack flexible, plastic container system led to Baxter's development of the VIAFLEX plastic IV bag. The technology applied eventually led to the development of a flexible, plastic container system for dialysis solutions that made possible continuous ambulatory peritoneal dialysis (CAPD), another Baxter first.
History
• 1962 - Baxter introduced first disposable blood oxygenator, making open-heart surgery possible.
• 1968 - introduced first commercially produced factor VIII concentrate to treat hemophilia.
• 1978 - Baxter introduced CAPD as a home-based alternative to hemodialysis. Sales exceeded $1 billion.
History
• 1985 - acquired American Hospital Supply Corp., becoming a broad-based healthcare products distributor
• 1995 - gained approval in Europe for its ISOLEX CD34+ stem-cell separator.
• 1996 - spun off its medical products distribution business, focus on core renal, biotechnology. Clearence from U.S. (FDA) for infusion pump.
History
• 1998 - acquired Ohmeda´s Pharmaceutical Products Division producing inhalation agents and drugs used for general and local anesthesia.
• 2007 - first needle-less IV connector with an antimicrobial coating.
History
• 2009 - European Commission granted marketing authorization CELVAPAN H1N1 pandemic influenza vaccine.
• 2011 - Baxter Ventures launched as a means to invest up to $200 mi. in equity on products and therapies, and accelerate innovation and growth. Acquire Baxa, mfgr automated compounding systems for parenteral nutrition.
Technology Identification
• Corporate Technology Sourcing CTS unit operates in an innovative and creative atmosphere. @ 6 staff & $500K
• Mission is to monitor new (unusual) external technological developments
• CTS looks for the unexpected and passes info onto technical & mktg dept
• Responds to specific requests
• No need to be right always, but creative
Technology Identification
• Transferred;
• Raspberry temperature measurement technique to use in continuous sterilization
• Japanese vending machine tehnology to use for automatic pharmacy machines
• 2% success
• → @5000 about 100 ideas are followed up; and 5-10% of projects are commercial success
• → resulting $30-40m annual revenues
Technology Identification
• Plans (policy) & forecasts i.e.
Technology Identification
• Plans (policy) & forecasts i.e.
Technology Identification
• Plans (policy) & forecasts i.e.
BioSurgery 2017 Market Potential = ~$8B
Anesthesia 2017 Market Potential = $1.2B
Nutritional Therapies 2017 Market Potential = $3.5B
Baxter Ventures
• Identifies companies with promising technologies, products, and provides the capital and expertise needed to drive successful innovation. Ventures created in 2011 by Baxter International
• CTS found in 1980s
• Has CTS Directors in EU and USA
• Baxter Ventures found on 2011
Baxter Ventures
• Invests in companies with innovative technologies, products and therapies with the ability to improve patient care globally and maximize value for investors and entrepreneurs.
• Interested in complementary solutions to current product range; as well as, cutting-edge technologies outside range
Baxter Ventures
• Application for Funding
• Company name, info, #employees
• Date Founded
• Total $ Funding Raised
• Product/Technology
• Market Opportunity
• Technical/Clinical Development Pathway
• Management Team
• Investment/Strategic Resources Requested
Further Discussions
• Baxter announced plans to create two independent companies 03/14
• Biopharmaceuticals (the spin-off)-Baxalta
• Medical products (%60 revenues)-Baxter
• Transaction (for spin-off) expected to be completed by 06/15
• Initial dis-synergies estimated at ~2% decline at total Baxter revenues
Questions & Closure
Thank you..